NCT03847246View on ClinicalTrials.gov

Bioequivalence Study of Entecavir Tablets and Baraclude® Under Fasting Condition in Chinese Healthy Volunteers

NACompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 4, 2018

Primary Completion Date

December 28, 2018

Study Completion Date

December 28, 2018

Conditions
Chronic Hepatitis b
Interventions
DRUG

Baraclude® tablets,1.0 mg

oral,once,under fasting condition

DRUG

Entecavir tablets,1.0 mg

oral,once,under fasting condition

Trial Locations (1)

250013

Ji'nan Central Hospital, Ji'nan

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY